% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

jjkimo 3 posts  |  Last Activity: Nov 1, 2015 7:31 PM Member since: Mar 8, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    $250 before YE 2015 will be an underestimation!

    by liv4ucf Sep 9, 2015 1:08 PM
    jjkimo jjkimo Nov 1, 2015 7:31 PM Flag

    181,000 cases multiplied by $61,000 per patient per year divided by 64,000,000 shares with a multiple of say 10 for the rest of the world and the per share price makes 250 look conservative. Keep your fingers crossed.

  • This MB is pretty entertaining with all the political b.s. that has been going on here now for years. But ETFC is getting their house in order and getting ready to make a run to some new levels. How about we switch gears and talk about ETFC once in awhile, considering this is a ETFC MB, and see if can make some money. This thing is getting ready to rock and roll upwards and who cares about Hillary or Rick Perry on this MB. The only thing the politicians are gonna do is take your money, so you better make as much as you can and this stock is a good place to be to offset their nonsense.

  • If all the gang shows back up with all the nonsence then we will know iplex is back on the table. Just IGFBP3 alone is worth some bucks.
    So let's see....I think Merck is still sitting on the manufacturing lab. "Follow on" biologics hasn't panned out quite the way they had hoped, and people are still getting their hands on Iplex for various reasons because that is what they want.
    Maybe even cocktail Iplex with various chemo drugs like they do now with Decadron and Benadryl and keep your body running smoothly while they go after the illness. Just a thought...

    Like I said, it should get interesting and this time we also have Arikayce in the loop which is a pretty spectacular item all on its own.

16.99+0.40(+2.41%)Nov 27 1:00 PMEST